{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+1+or+Type+2+Diabetes", "query": { "condition": "Type 1 or Type 2 Diabetes" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+1+or+Type+2+Diabetes&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T12:03:04.587Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00453934", "title": "Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes", "Type 2 Diabetes" ], "interventions": [ { "name": "h-Patch", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Valeritas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2007-05", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2007-12-06", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453934" }, { "nct_id": "NCT05088265", "title": "Bigfoot Unity Real World Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 1 or Type 2 Diabetes" ], "interventions": [ { "name": "Bigfoot Unity Diabetes Management System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Bigfoot Biomedical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 500, "start_date": "2021-10-26", "completion_date": "2025-02", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 1, "location_summary": "Milpitas, California", "locations": [ { "city": "Milpitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05088265" }, { "nct_id": "NCT00384085", "title": "Insulin Glargine \"All to Target\" Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Glulisine", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Premixed Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 588, "start_date": "2006-05", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-05-06", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384085" }, { "nct_id": "NCT04265261", "title": "A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RG7774", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2020-06-05", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04265261" }, { "nct_id": "NCT04305054", "title": "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Favezelimab/Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 335, "start_date": "2020-07-01", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305054" }, { "nct_id": "NCT07104500", "title": "VK2735 for Weight Management Phase 3", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Weight Loss" ], "interventions": [ { "name": "VK2735", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viking Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4500, "start_date": "2025-06-23", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07104500" }, { "nct_id": "NCT06845202", "title": "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Obese or Overweight Healthy Volunteers", "Type 2 Diabetes Mellitus (T2DM)" ], "interventions": [ { "name": "ALN-4324", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 105, "start_date": "2025-03-03", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 7, "location_summary": "Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more", "locations": [ { "city": "Montclair", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Monroe", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06845202" }, { "nct_id": "NCT06865989", "title": "Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 1, Type 2" ], "interventions": [ { "name": "Omnipod 5 SmartAdjust 2.0 System", "type": "DEVICE" }, { "name": "Omnipod 5 System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Insulet Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 132, "start_date": "2025-03-26", "completion_date": "2025-11-10", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865989" }, { "nct_id": "NCT00642616", "title": "Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus", "Moderate Chronic Obstructive Pulmonary Disease", "Asthma" ], "interventions": [ { "name": "Technosphere® Insulin", "type": "DRUG" }, { "name": "Usual Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2009-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2017-04-14", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 12, "location_summary": "Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more", "locations": [ { "city": "Mission Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Flint", "state": "Michigan" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642616" }, { "nct_id": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Soft Tissue Sarcoma (STS)", "Platinum-resistant Ovarian Cancer (PROC)", "Hepatocellular Carcinoma (HCC)", "Colorectal Cancer (CRC)", "HER2 Negative Breast Cancer", "Cutaneous Melanoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "GI-102 subcutaneous (SC)", "type": "DRUG" }, { "name": "GI-102", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "eribulin", "type": "DRUG" }, { "name": "trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2023-05-30", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-07-24T12:03:04.587Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05824975" } ] }